The University of Chicago Header Logo

A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder.

A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder. Br J Psychiatry. 2021 Nov 17; 1-6.

View in: PubMed